ASLAN Pharmaceuticals today announced further progress towards a primary listing on the Nasdaq Global Market (“Nasdaq”) and receipt of a Notice of Delisting from the Taipei Exchange (“TPEx”), an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares (“ADS”) on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement.

For more information, please refer to the English release and FAQ document.

If you are a Taiwan shareholder holding shares in ASLAN, refer to this release and FAQ document.